Jason Gardner co-founded Magenta Therapeutics while an Entrepreneur-in-Residence at Atlas Venture working with Third Rock Ventures. Prior to Magenta, Jason was at GSK, most recently as Vice President and Head of the R&D Satellite in Boston. He created and led the Regenerative Medicine Unit and established partnerships with the Harvard Stem Cell Institute and the San Raffaele Telethon Institute for Gene Therapy, from which the first stem cell medicine (Strimvelis®) was approved. Prior to that, Jason held leadership roles in business development and was a member of the team that led the late stage development and NDA approval for Tykerb® for breast cancer. Prior to GSK, Jason was a scientist at Chiron Corporation and Progenics Pharmaceuticals.
Jason completed a postdoctoral fellowship in hematopoietic stem cells with Professor David Scadden at Harvard Medical School. He was educated in the UK and holds a doctorate from Oxford University and graduate and undergraduate degrees from Cambridge University.